Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis

被引：0
|
作者：
Girard, N. [1 ]
Leighl, N. [2 ]
Ohe, Y. [3 ]
Kim, T. M. [4 ]
Demirdjian, L. [5 ]
Bourla, A. B. [5 ]
Sultan, A. Abdul [6 ]
Mahadevia, P. [5 ]
Bauml, J. M. [5 ]
Sabari, J. [7 ]
机构：
[1] Inst Curie, Paris, France
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Natl Canc Ctr, Tokyo, Japan
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Janssen R&D, Spring House, PA USA
[6] Janssen Global Commercial Strategy Org RWE, Raritan, NJ USA
[7] New York Univ Langone Hlth, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19P
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [1] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Jorge Nieva
    Karen L. Reckamp
    Danielle Potter
    Aliki Taylor
    Ping Sun
    [J]. Drugs - Real World Outcomes, 2022, 9 : 333 - 345
  • [2] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Nieva, Jorge
    Reckamp, Karen L.
    Potter, Danielle
    Taylor, Aliki
    Sun, Ping
    [J]. DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 333 - 345
  • [3] US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment
    Reckamp, K.
    Nieva, J.
    Taylor, A.
    Thakrar, B.
    Wong, J.
    Potter, D.
    Bakker, N.
    Rubinstein, W.
    Sun, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S402 - S402
  • [4] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie P. L.
    Low, Yi Fen
    Lai, Gillianne G. Y.
    Chan, Landon L.
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia H.
    Seet, Amanda O. L.
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan -Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren W. T.
    Tan, Daniel S. W.
    Mok, Tony S. K.
    Li, Molly S. C.
    [J]. LUNG CANCER, 2024, 193
  • [5] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie Pei Li
    Low, Yi Fen
    Lai, Gillianne
    Chan, Landon
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia
    Seet, Amanda Oon Lim
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren Wan-Teck
    Tan, Daniel Shao-Weng
    Mok, Tony S. K.
    Li, Molly Sc
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Real-World-Data on First-Line Therapy with Osimertinib in Patients with advanced EGFR-mutated NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Shenolikar, R.
    Shaw, S.
    [J]. PNEUMOLOGIE, 2021, 75 : S11 - S11
  • [7] US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment
    Nieva, J.
    Reckamp, K.
    Taylor, A.
    Thakrar, B.
    Wong, J.
    Potter, D.
    Bakker, N.
    Rubinstein, W.
    Sun, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S399
  • [8] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hayashi, Hidetoshi
    Nishio, Makoto
    Takahashi, Michiko
    Tsuchiya, Hiroaki
    Kasahara-Kiritani, Mami
    [J]. ADVANCES IN THERAPY, 2023, 40 (10) : 4545 - 4560
  • [9] Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1690
  • [10] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hidetoshi Hayashi
    Makoto Nishio
    Michiko Takahashi
    Hiroaki Tsuchiya
    Mami Kasahara-Kiritani
    [J]. Advances in Therapy, 2023, 40 : 4545 - 4560
12345